EXULT KNEE: Optimization of Dose (Study A) and Confirmation of Safety and Efficacy (Study B) of H 376/95 (Oral Direct Thrombin Inhibitor ximelagatran) Compared to Warfarin (COUMADIN) for the Prevention of Venous Thromboembolism Following Total Knee Arthroplasty

Study identifier:SH-TPO-0012

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

EXULT KNEE: Optimization of Dose (Study A) and Confirmation of Safety and Efficacy (Study B) of H 376/95 (Oral Direct Thrombin Inhibitor ximelagatran) Compared to Warfarin (COUMADIN) for the Prevention of Venous Thromboembolism Following Total Knee Arthroplasty

Medical condition

venous thromboembolism

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jun 2002
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria